Coherus Knocks Out One Humira Patent But Others Block Biosimilars
Executive Summary
Patent Trial and Appeal Board invalidates patent on method to treat rheumatoid arthritis; next hurdle is overcoming formulation patents that do not expire until 2022.
You may also be interested in...
PTAB Tosses Two More Humira Patents; Will Supreme Court Eliminate IPR Proceeding?
Patent Trial and Appeal Board rules for Coherus in its challenge of Humira patents and takes up review of Cialis patent. US high court to consider constitutionality of inter partes review proceeding.
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.